SARS-CoV-2 virus can not only damage the respiratory system but may also pose a threat to other organs, such as the heart or vessels. This review focuses on cardiovascular complications of COVID-19, including acute cardiac injury, arrhythmias, biomarkers, accompanying comorbidities and outcomes in patients diagnosed with SARS-CoV-2 infection. The research was conducted on the databases: PubMed, Springer, ScienceDirect, UpToDate, Oxford Academic, Wiley Online Library, ClinicalKey. Fifty-six publications from 1 November 2020 till 15 August 2021 were included in this study. The results show that cardiac injury is present in about 1 in 4 patients with COVID-19 disease, and it is an independent risk factor, which multiplies the death rate several times in comparison to infected patients without myocardial injury. New-onset cardiac injury occurs in nearly every 10th patient of the COVID-19-suffering population. Comorbidities (such as hypertension, cardiovascular disease and diabetes) severely deteriorate the outcome. Therefore, patients with SARS-CoV-2 infection should be carefully assessed in terms of cardiac medical history and possible cardiological complications.
Purpose: The risk of epiphora after medial maxillectomy with lacrimal duct transection is difficult to assess. The data available in the literature are inconclusive due to various operating techniques used by the authors of medical publications, different additional procedures aimed at improving tear drainage after maxillectomy, and a variety of lacrimal duct patency assessment techniques. The aim of our work was to assess the anatomical and functional patency of lacrimal ducts after medial maxillectomy without performing additional procedures to improve tear drainage as well as comparison of the results obtained with different assessment tests. Materials and methods: 21 patients who underwent medial maxillectomy in the years 2016–2019 were assessed for discomfort and epiphora based on patients’ own reports and basic clinical examination, lacrimal duct rinse test, the Munk score, and a modified endoscopic Jones I test. Results: Gradually increasing the sensitivity of the assessment method resulted in an increase in the number of patients with potential tear drainage disorders, starting from 0% in the rinsing test, 4.8% self-reported tearing complaints, 14.3% Munk score, and 19% modified endoscopic Jones I test. Conclusions: The study results revealed that a small fraction of patients tend to report epiphora as a consequence of medial maxillectomy themselves. Subtle functional disorders, which are not particularly bothersome to patients, are more common. More sensitive lacrimal duct patency tests reveal more cases of tear drainage disorders. The results of studies assessing the incidence of epiphora after medial maxillectomy appear to depend on the type of test used.
Background: Neurogenic bladder due to myelomeningocele (MMC) is a significant risk factor for chronic kidney disease in children. Cystatin C (CysC) is a more accurate GFR marker than creatinine as it is unaffected by muscle mass but may be influenced by fat mass and BMI. This study evaluates: (1) GFR measurement accuracy using CysC and creatinine in MMC-related neurogenic bladder, (2) the relationship between body composition via bioelectrical impedance analysis (BIA) and renal parameters, and (3) the use of BIA for non-invasive GFR and body composition assessment. Methods: Forty children (median age 9.96 years) underwent serum creatinine, CysC testing, and BIA measurements. We assessed age, sex, spinal lesion level, anthropometric measurements, BMI, and activity using Hoffer’s scale. GFR was calculated using five creatinine-based formulas, three CysC-based, and three combining CysC and creatinine, including BIA GFR as an alternative approach. Results: Creatinine-based GFR estimates were significantly higher than CysC-based GFR. Although only 30% of MMC patients met the traditional BMI criteria for overweight/obesity, 62.5% were obese based on BIA-measured body fat percentage. Significant differences were found in CysC and CysC-based GFR equations within BMI and fat mass groups. Positive correlations were observed between CysC and body weight, BMI percentiles, body fat mass and fat-to-muscle ratio. Muscle mass positively correlated with creatinine. Conclusions: BIA-determined fat mass percentage is a more sensitive obesity indicator than BMI in MMC patients. CysC levels and CysC-based GFR equations are influenced by body fat mass, requiring consideration of adiposity to avoid misestimating renal impairment. Graphical
Introduction: Tumor necrosis factor (TNF)-like cytokine 1A (TL1A) is a member of the TNF superfamily of cytokines, involved in regulation of the immune and inflammatory response. Recently, therapies aimed at blockade of the TL1A pathway have shown benefit in the treatment of inflammatory bowel diseases (IBDs). However, very little is known regarding activation of the TL1A axis in spondyloarthropathies (SpA), which are clinically and pathogenetically linked to IBDs. Our study investigated soluble forms of TL1A and its receptors, death receptor 3 (DR3) and decoy receptor 3 (DcR3), in the serum of patients with SpA, and evaluated potential associations between concentrations of the investigated molecules and clinical features of SpA.Material and methods: Tumor necrosis factor-like cytokine 1A, DR3, and DcR3 concentrations were measured (using enzyme linked immunosorbent assay – ELISA) in the serum of 82 patients with SpA and 36 healthy controls.Results: We found no significant difference in serum concentrations of TL1A or DR3 between the study and the control groups. However, we observed a significantly higher concentration of DcR3 (median [min.–max.]: 292.31 [93.241–13,862.10] pg/ml) in patients with SpA than in the controls (median [min.–max.]: 126.73 [10.68–1,482.74] pg/ml; p = 0.003). The DR/DcR ratio was significantly lower in patients with SpA (median [min.–max.]: 4.05 [0.14–235.39]) than in the controls (17.22 [0.00–750.66]; p = 0.002). Moreover, there were weak but significant correlations between serum concentrations of DcR and TL1A (Spearman’s rho: 0.28, p < 0.05) and between DcR3 and C-reactive protein as well as erythrocyte sedimentation rate values (Spearman’s rho: 0.25 and 0.24 respectively, p < 0.05 for both) in patients with SpA.Conclusions: The results of our study indicate that the TL1A/DR3/DcR3 axis is activated in patients with SpA and may represent a new target for therapies in this group of diseases. Further studies are needed to confirm our data.
Spondyloarthropathies (SpA) are a broad and diverse group of diseases with highly variable clinical manifestations. Due to this wide range of symptoms and their frequent overlap with other disease entities, SpA present numerous diagnostic and therapeutic challenges. Moreover, the pathogenesis of SpA remains unexplained. While the currently prevailing hypothesis suggests an autoinflammatory mechanism, the involvement of autoimmune processes has not been ruled out. To explore this possibility, the present study aimed to assess the presence of antinuclear antibodies (ANA) and their clinical associations in patients with SpA. The analysis included 117 consecutive patients with different forms of SpA, i.e., ankylosing spondylitis (n = 52), psoriatic arthritis (n = 34), and non-radiographic SpA (n = 31). They underwent clinical evaluation, and serum samples were collected from each for ANA testing using indirect immunofluorescence. ANA were found in 46% of patients with SpA. No statistically significant association was found between ANA and diagnosis of specific SpA or clinical symptoms. Interestingly, the highest prevalence of ANA (63%) was found in women with non-radiographic spondyloarthropathy and the lowest (38%) in males with ankylosing spondylitis, however, the difference did not reach statistical significance. The results of our study suggest that ANA are frequent in patients with SpA, in particular in women with early, non-radiographic SpA which may be of clinical significance. However, further studies, involving larger populations, are necessary to clarify the significance of ANA presence in SpA patients.